ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1907

Pharmacological Management of Gout in Italy in the Years 2005-2009: A Nationwide, Population-Based Study

Lorenzo Cavagna1, Gianluca Trifirò2, Roberto Caporali3, P. Morabito2, C. Ferrajolo4, S. Pecchioli5, M. Simonetti5, G. Medea6, C. Cricelli7, A. Caputi2, G. Mazzaglia5 and Carlomaurizio Montecucco8, 1Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 2Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy, 3Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, 4Department of Experimental Medicine, Pharmacology Section, Second University of Naples, Naples, Italy, 5Health Search, Italian College of General Practitioners, Italy, 6Italian college of General Practitioner, Italy, 7Italian college of General Practitioner, Pavia (italy), Italy, 8Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: gout, hyperuricemia and prescribing trends

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Despite the increasing interest on gout, only few nationwide drug utilization studies have been conducted on this topic. The aim of this study was to investigate the Italian prescribing pattern of medications for gout in the years 2005-9

Methods: The data source of the study was the national Database of the Italian College of General practitioner, covering about 1.5 million patients from all around Italy. Patients with incident gout (years 2005-9) were identified using specific ICD9-CM codes and related key words for free text search. In this cohort of patients, we measured the yearly prevalence of use of the following drugs: allopurinol (ATC: M04AA01); colchicine (M04AC01); NSAIDs (M01A*). Moreover,  systemic corticosteroids (H02*) were taken into account, because frequently used during acute attacks. Drugs not marketed in Italy, or not reimbursed by National Health System (probenecid, sulfinpirazone and benzbromarone) were not taken into account. For allopurinol rate and predictors of persistence and adherence to the treatment have been evaluated too.

Results: During the study period, 3,069 patients with incident gout were identified. Allopurinol prescription in these patients decreased from 45.2% in 2005 to 41.1% in 2009. Among drugs for the acute attack of gout, NSAIDs (from 41.9% in 2005 to 39.8% in 2009) were significantly more prescribed than colchicine (from 4.5% in 2005 to 4.9% in 2009). Corticosteroids were prescribed in a significant proportion of patients (from 12.3% in 2005 to 12.4% in 2009) during the whole study period. Only 22.7% of patients continued allopurinol after three months from the beginning of the therapy (6.6% after 6 months, 1.6% after one year). For allopurinol, the proportion of days covered (PDC)  was on average equal to 39%. The proportion of patients with high adherence to the treatment (PDC >80%) increased with advancing age and was significantly higher in males. Hypertension, obesity, cerebrovascular diseases, congestive heart failure and sUA levels > 9mg/dl, enhanced allopurinol treatment adherence

Conclusion: to our knowledge, this is the first drug-utilization study on pharmacological management of gout in Italian general population. Our results were quite similar to that recently described in US population, although in this study the prevalence of colchicine (16.7%) and corticosteroids (21%) prescription was higher than those we observed. Our data show very low levels of persistence and adherence to allopurinol treatment; non-adherence was particularly common in younger patients, with lower serum urate levels and burden of comorbidities, as suggested in a recent survey. Clinicians should motivate low risk patients to increase the level of adherence to the treatment for the prevention of gout


Disclosure:

L. Cavagna,
None;

G. Trifirò,
None;

R. Caporali,
None;

P. Morabito,
None;

C. Ferrajolo,
None;

S. Pecchioli,
None;

M. Simonetti,
None;

G. Medea,
None;

C. Cricelli,
None;

A. Caputi,
None;

G. Mazzaglia,
None;

C. Montecucco,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacological-management-of-gout-in-italy-in-the-years-2005-2009-a-nationwide-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology